Compare
Nu Skin Enterprises, Inc. vs Cosmos Health Inc. vs Stemtech Corp
| Latest fiscal year | Nu Skin Enterprises, Inc. NUS | Cosmos Health Inc. COSM | Stemtech Corp STEK |
|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.49B | $65.27M | $2.88M |
| Revenue growth (YoY) | -14.3% | +19.9% | -43.1% |
| Gross margin | 69.4% | 12.1% | 80.3% |
| Operating margin | 4.4% | -25.6% | -94.2% |
| Net margin | 10.8% | -29.3% | -140.7% |
| Net income | $160.20M | -$19.14M | -$4.05M |
| EPS (Diluted) | $3.18 | -$0.63 | -$0.02 |
| Operating cash flow | $80.29M | -$8.45M | -$483.6K |
| Free cash flow | $46.01M | -$8.50M | -$483.6K |
| Cash & equivalents | $238.63M | $715.7K | n/a |
| Total assets | $1.41B | $65.48M | $3.15M |
| Total liabilities | $600.07M | $47.05M | $10.59M |
| Shareholders' equity | $805.24M | $18.42M | -$6.96M |
| Return on year-end equity | 19.9% | -103.9% | n/a |
| Shares outstanding | n/a | 41.07M | 425.98M |
Revenue, most recent five fiscal years
| Fiscal year | Nu Skin Enterprises, Inc. | Cosmos Health Inc. | Stemtech Corp |
|---|---|---|---|
| Latest | $1.49B Ended 2025-12-31 | $65.27M Ended 2025-12-31 | $2.88M Ended 2025-12-31 |
| 1 year earlier | $1.73B Ended 2024-12-31 | $54.43M Ended 2024-12-31 | $5.05M Ended 2024-12-31 |
| 2 years earlier | $1.97B Ended 2023-12-31 | $53.38M Ended 2023-12-31 | $4.92M Ended 2023-12-31 |
| 3 years earlier | $2.23B Ended 2022-12-31 | $50.35M Ended 2022-12-31 | $4.56M Ended 2022-12-31 |
| 4 years earlier | $2.70B Ended 2021-12-31 | $56.24M Ended 2021-12-31 | $4.32M Ended 2021-12-31 |